Abstract：
BACKGROUND: Enthesitis is a key feature of spondyloarthropathy (SpA). In recent years, JAK inhibitors have emerged as efficacious drugs in the landscape of advanced therapies for patients with SpA.
METHODS: The aim of this scoping literature review was to search the published literature for studies on JAK inhibitors and their effects on enthesitis in patients with SpA and evaluate the data and summarise the findings. The clinical trials reviewed used the Leeds Enthesitis Index, Spondyloarthritis Research Consortium of Canada Enthesitis Index, and Maastrich Ankylosing Spondylitis Enthesitis Score as outcome measures.
RESULTS: Tofacitinib, upadacitinib, and filgotinib had numerically greater reductions in the enthesitis scores when compared with placebo.
CONCLUSIONS: While the JAK inhibitors are therapeutic options for enthesitis in SpA, head-to-head studies are needed to compare the JAK inhibitors against the biological drugs (targeting TNF, IL-17, and IL-12/23) as well as studies showing the effects of JAK inhibitors on enthesitis imaging.
METHODS: The aim of this scoping literature review was to search the published literature for studies on JAK inhibitors and their effects on enthesitis in patients with SpA and evaluate the data and summarise the findings. The clinical trials reviewed used the Leeds Enthesitis Index, Spondyloarthritis Research Consortium of Canada Enthesitis Index, and Maastrich Ankylosing Spondylitis Enthesitis Score as outcome measures.
RESULTS: Tofacitinib, upadacitinib, and filgotinib had numerically greater reductions in the enthesitis scores when compared with placebo.
CONCLUSIONS: While the JAK inhibitors are therapeutic options for enthesitis in SpA, head-to-head studies are needed to compare the JAK inhibitors against the biological drugs (targeting TNF, IL-17, and IL-12/23) as well as studies showing the effects of JAK inhibitors on enthesitis imaging.
摘要：
背景：结膜炎是脊柱关节病（SpA）的一个关键特征。近年来,JAK抑制剂已成为SpA患者的高级疗法中的有效药物。
方法：本范围文献综述的目的是检索已发表的文献中关于JAK抑制剂及其对SpA患者附着点炎的影响的研究，并对数据进行评估和总结。审查的临床试验使用了利兹端炎指数，加拿大脊柱炎研究联盟，和Maastrich强直性脊柱炎端炎评分作为结果指标。
结果：托法替尼，upadacitinib,与安慰剂相比,菲尔戈替尼在附着点炎评分方面的降低幅度更大.
结论：虽然JAK抑制剂是SpA附着性炎的治疗选择，需要进行头对头研究，以比较JAK抑制剂与生物药物（靶向TNF，IL-17和IL-12/23）以及显示JAK抑制剂对附着点炎成像影响的研究。
方法：本范围文献综述的目的是检索已发表的文献中关于JAK抑制剂及其对SpA患者附着点炎的影响的研究，并对数据进行评估和总结。审查的临床试验使用了利兹端炎指数，加拿大脊柱炎研究联盟，和Maastrich强直性脊柱炎端炎评分作为结果指标。
结果：托法替尼，upadacitinib,与安慰剂相比,菲尔戈替尼在附着点炎评分方面的降低幅度更大.
结论：虽然JAK抑制剂是SpA附着性炎的治疗选择，需要进行头对头研究，以比较JAK抑制剂与生物药物（靶向TNF，IL-17和IL-12/23）以及显示JAK抑制剂对附着点炎成像影响的研究。
